BD HorizonTM R718 Biosimilar Anti-Human HER2

Description

Flow cytometric analysis of HER2 Trastuzumab Biosimilar expression on viable Human SK-BR-3 cells. Cells from the Human SK-BR-3 Breast adenocarcinoma, ATCC HTB-30 cell line were preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564220 and then stained with either BD OptiBuild R718 IgG1, kappa N297A Human Isotype Control Cat. No. 756246; dashed line histogram or BD Horizon R718 Biosimilar Anti-Human HER2 antibody Cat. No. 570383/570453; solid line histogram . DAPI 4,6-Diamidino-2-Phenylindole, Dihydrochloride Solution Cat. No. 564907 was added to cells right before analysis. The fluorescence histogram showing HER2 Trastuzumab Biosimilar expression or Ig Isotype control staining was derived from gated events with the forward and side light-scatter characteristics of viable DAPI-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo Software. Flow cytometric analysis of HER2 Trastuzumab Biosimilar expression on viable Human SK-BR-3 cells. Cells from the Human SK-BR-3 Breast adenocarcinoma, ATCC HTB-30 cell line were preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564220 and then stained with either BD OptiBuild R718 IgG1, kappa N297A Human Isotype Control Cat. No. 756246; dashed line histogram or BD Horizon R718 Biosimilar Anti-Human HER2 antibody Cat. No. 570383/570453; solid line histogram . DAPI 4,6-Diamidino-2-Phenylindole, Dihydrochloride Solution Cat. No. 564907 was added to cells right before analysis. The fluorescence histogram showing HER2 Trastuzumab Biosimilar expression or Ig Isotype control staining was derived from gated events with the forward and side light-scatter characteristics of viable DAPI-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo Software. Show More Flow cytometric analysis of HER2 Trastuzumab Biosimilar expression on viable Human SK-BR-3 cells. Cells from the Human SK-BR-3 Breast adenocarcinoma, ATCC HTB-30 cell line were preincubated with BD Pharmingen Human BD Fc Block Cat. No. 564220 and then stained with either BD OptiBuild R718 IgG1, kappa N297A Human Isotype Control Cat. No. 756246; dashed line histogram or BD Horizon R718 Biosimilar Anti-Human HER2 antibody Cat. No. 570383/570453; solid line histogram . DAPI 4,6-Diamidino-2-Phenylindole, Dihydrochloride Solution Cat. No. 564907 was added to cells right before analysis. The fluorescence histogram showing HER2 Trastuzumab Biosimilar expression or Ig Isotype control staining was derived from gated events with the forward and side light-scatter characteristics of viable DAPI-negative cells. Flow cytometry and data analysis were performed using a BD LSRFortessa Cell Analyzer System and FlowJo Software.